Molecule Details
| InChIKey | GHBCIXGRCZIPNQ-MHZLTWQESA-N |
|---|---|
| Canonical SMILES | COc1ccc2c(c1OCc1ccccc1)C[C@@H](C(=O)O)N(C(=O)C(c1ccccc1)c1ccccc1)C2 |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 8.28 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB16266 |
|---|---|
| Drug Name | Olodanrigan |
| CAS Number | 1316755-16-4 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Olodanrigan is under investigation in clinical trial NCT03297294 (Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)). |
Categories: Benzene Derivatives Heterocyclic Compounds, Fused-Ring
Cross-references: BindingDB: 50049182 CHEMBL34124 ChemSpider: 8112918 PDB: VFD ZINC: ZINC000001483494
Target Activities (2)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| P50052 | AGTR2 | Type-2 angiotensin II receptor | antagonist | targets |